Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
Lutetium-177 PNT2002 for Prostate Cancer | Open Medscience
PNT2002 / POINT Biopharma, Lantheus
Anticipated Timelines PNT2002 (Prostate Cancer) PNT2003 (SSRT+ non-GEP ...
Structure of protein By KK Sahu Sir | PPT
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
(R)-Zadavotide guraxetan ((R)-PSMA I&T) | PSMA Inhibitor | MedChemExpress
Frontiers | Initial clinical experience with [177Lu]Lu-PNT2002 ...
ESMO 22: Results of the 177Lu-PNT2002 SPLASH Trial | GU Oncology Now
Dose‐adapted stereotactic body radiation therapy based on the response ...
A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [177Lu ...
[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer ...
Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical ...
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy ...
177Lu-Labeled Albumin-Binder–Conjugated PSMA-Targeting Agents with ...
Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate ...
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC
ASCO 2021: Study Evaluating Metastatic Castrate Resistant Prostate ...
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC | Urology Times
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC | Targeted ...
177Lu-PNT2002 Received FDA Fast Track Designation for Metastatic CRPC
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC
[Lu-177]-PNT2002 for Prostate Cancer Clinical Trial 2023 | Power
177Lu–Prostate-specific Membrane Antigen Radioligand Therapy in ...
PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis ...
ESMO 2022: Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific ...
slide16
slide15
Prostate Cancer Molecular Imaging and Therapy in MIRROR and 177Lu ...
Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA ...
LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following ...
作为靶向前列腺特异性膜抗原的治疗性放射性药物的177Lu-DOTA-HYNIC-iPSMA的制作方法
【速递】礼来收购PSMA核药变故？从市场竞争角度分析医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
PSMA-Targeting Radioligand Therapy in Prostate Cancer | Published in ...
ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate
Preclinical Evaluation of a New Series of Albumin-Binding 177Lu-Labeled ...
New therapy delays progression of recurrent prostate cancer | UCLA Health
Study on Treating Metastatic Castration-Resistant Prostate Cancer with ...
Planar scintigraphic images of ²⁰³Pb-labelled compounds in C4-2 ...
AUA 2024: mCRPC: Key Updates in Radioligand Therapy, PSMA Sensitive Disease
Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following Progression ...
Lutetium Lu 177 Dotatate Radioequivalent Receives Tentative FDA ...
177Lu-PNT2002 Meets Primary Endpoint in Phase III mCRPC Trial ...
Frontiers | 177Lu-labeled PSMA targeting therapeutic with optimized ...
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant ...
Optimized Therapeutic 177Lu-Labeled PSMA-Targeted Ligands with Improved ...
PSMA and Beyond 2025: Overview of Clinical Trials of PSMA RLT in 2025
ESMO24 - 177Lu-PNT2002 bemoedigend na progressie op AR-pathwayremmer ...
slide13
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate ...
Peptide-Radionuclide Conjugates: Interpretation of FDA Approved Drugs ...
Chemical structures of 177 Lu-PSMA-617 and 177 Lu-PSMA I&T. | Download ...
177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic ...
核药赛道探险者：POINT Biopharma，扎根高端用药布局_摩熵医药(原药融云)
Lilly Plans to Purchase POINT Biopharma, Enhancing Cancer Treatment ...
Matched-Pair Analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in ...
ESMO 2025: 177Lutetium-PSMA Therapy Neoadjuvant to Stereotactic ...
POINT生物制药在PNT2002的3期SPLASH试验中完成随机化 - 中国核技术网
:%0A%0A[Lu-177]-PNT2002%20for%20Prostate%20Cancer.png?md=1)
